All In Biotech

Drug Trial Radar · NCT00862641

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

A Phase 4, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD).

Last checked: Nov 20, 2026Latest source record: Sep 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,009 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,009

Actual

Start

Apr 2009

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Mar 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is intended to determine the safety and tolerance of regadenoson in subjects with asthma or chronic obstructive pulmonary disease.

Conditions

  • Asthma
  • Coronary Artery Disease
  • Pulmonary Disease, Chronic Obstructive

Interventions

  • RegadenosonDrug

    IV

  • PlaceboDrug

    IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Who Had a >15% Decrease in Forced Expiratory Volume in 1 Second (FEV1) at the 2-hour Postbaseline AssessmentTime frame: 2 Hours post dose

Locations

48 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Montgomery, Alabama

  • Site not named

    Anaheim, California

  • Site not named

    Encinitas, California

  • Site not named

    Fullerton, California

  • Site not named

    Huntington Beach, California

  • Site not named

    Long Beach, California

  • Site not named

    Mission Viejo, California

  • Site not named

    Roseville, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Waterbury, Connecticut

  • Site not named

    Newark, Delaware

  • Site not named

    Wilmington, Delaware

  • Site not named

    Clearwater, Florida

  • Site not named

    DeLand, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Trinity, Florida

  • Site not named

    Winter Park, Florida

  • Site not named

    Stockbridge, Georgia

  • Site not named

    Aurora, Illinois

  • Site not named

    Topeka, Kansas

  • Site not named

    Shreveport, Louisiana

  • Site not named

    Auburn, Maine

  • Site not named

    No. Dartmouth, Massachusetts

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Plymouth, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Papillion, Nebraska

  • Site not named

    Brick, New Jersey

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Chardon, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Medford, Oregon

  • Site not named

    Upland, Pennsylvania

  • Site not named

    Providence, Rhode Island

  • Site not named

    Charleston, South Carolina

  • Site not named

    Easley, South Carolina

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.